



NEWS RELEASE

# CRINETICS PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2023

2023-09-20

SAN DIEGO – September 20, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1×1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

Details of the fireside chat are as follows:

Date: Tuesday, September 26, 2023

Time: 1:00 p.m. Eastern Time

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics' website on **our events page**.

If you are interested in arranging a 1×1 meeting with management, please contact your Cantor representative.

## About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. **Paltusotine**, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for **CRN04894** a first-in-class,

investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing's disease and congenital adrenal hyperplasia. All of the Company's **drug candidates** are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

---

Contact:

Chas Schultz

VP, IR & Corporate Communications

**cschultz@crinetics.com**

**(858) 450-6464**

Investors / Media:

Corey Davis

LifeSci Advisors

**cdavis@lifesciadvisors.com**

**(212) 915-2577**

Jenn Gordon

Spectrum Science

**jgordon@spectrumsience.com**

**(202) 957-7795**

Source: Crinetics Pharmaceuticals, Inc.